Patient Rating:

No Rating Available?

Stephen L. Lessnick, M.D., Ph.D.

Specialties

Languages

  • English

Clinical Details

Locations

Schedule An Appointment Clinical Office Address
(801) 662-4700 Primary Children's Hospital
Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City, UT 84113

Bio

Stephen Lessnick, MD, PhD, is a Huntsman Cancer Institute (HCI) investigator and member of the Nuclear Control of Cell Growth and Differentiation program. He is a Professor in the Division of Pediatric Hematology/Oncology, Department of Pediatrics at the University of Utah School of Medicine, as well as an Adjunct Professor in the Department of Oncological Sciences, and an Adjunct Professor in the Department of Bioengineering. He is the Director of the Center for Children's Cancer Research. He holds a Jon and Karen Huntsman Presidential Professorship in Cancer Research.

The Lessnick Lab studies Ewing's sarcoma as a model for pediatric tumor development. Ewing's sarcoma is a prototypical tumor that has a peak incidence in the teenage years. A chromosomal translocation (an abnormality that occurs when chromosomes break and the fragments rejoin to other chromosomes) characterizes Ewing's sarcoma. Learning details of how the cancer-causing protein created by this translocation functions could help resolve questions about the differences between pediatric and adult tumors, and between sarcomas and other forms of cancer. Additionally, the Lessnick Lab is interested in developing new therapeutic interventions for children with cancer.

Dr. Lessnick earned his bachelor's degree from Brandeis University followed by MD and PhD degrees from the University of California, Los Angeles (UCLA) as part of the Medical Scientist Training Program (MSTP). He conducted his internship and residency at Children's Hospital in Boston, Massachusetts, followed by a fellowship in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Children's Hospital. His fellowship/postdoctoral research was performed in the Pediatric Oncology Department at the Dana-Farber Cancer Institute.

Board Certification and Academic Information

Academic Departments Pediatrics - Professor
Oncological Sciences - Adjunct Professor
Orthopaedics - Adjunct Professor
Academic Divisions Pediatric Hematology/Oncology
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Profile

Research Interests

  • Pediatric Cancer Biology
  • Ewing's Sarcoma
  • Pediatric Cancer Development

Board Certification and Academic Information

Academic Departments Pediatrics - Professor
Oncological Sciences - Adjunct Professor
Orthopaedics - Adjunct Professor
Academic Divisions Pediatric Hematology/Oncology
Cancer Center Programs Nuclear Control of Cell Growth & Differentiation

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-9268 Huntsman Cancer Institute
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Stephen Lessnick, MD, PhD, is a Huntsman Cancer Institute (HCI) investigator and member of the Nuclear Control of Cell Growth and Differentiation program. He is a Professor in the Division of Pediatric Hematology/Oncology, Department of Pediatrics at the University of Utah School of Medicine, as well as an Adjunct Professor in the Department of Oncological Sciences, and an Adjunct Professor in the Department of Bioengineering. He is the Director of the Center for Children's Cancer Research. He holds a Jon and Karen Huntsman Presidential Professorship in Cancer Research.

The Lessnick Lab studies Ewing's sarcoma as a model for pediatric tumor development. Ewing's sarcoma is a prototypical tumor that has a peak incidence in the teenage years. A chromosomal translocation (an abnormality that occurs when chromosomes break and the fragments rejoin to other chromosomes) characterizes Ewing's sarcoma. Learning details of how the cancer-causing protein created by this translocation functions could help resolve questions about the differences between pediatric and adult tumors, and between sarcomas and other forms of cancer. Additionally, the Lessnick Lab is interested in developing new therapeutic interventions for children with cancer.

Dr. Lessnick earned his bachelor's degree from Brandeis University followed by MD and PhD degrees from the University of California, Los Angeles (UCLA) as part of the Medical Scientist Training Program (MSTP). He conducted his internship and residency at Children's Hospital in Boston, Massachusetts, followed by a fellowship in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Children's Hospital. His fellowship/postdoctoral research was performed in the Pediatric Oncology Department at the Dana-Farber Cancer Institute.

Education

Education History

Type School Degree
Postdoctoral Fellowship Dana-Farber Cancer Institute - Todd Golub, MD
Hematology/Oncology
Postdoctoral Fellow
Fellowship Dana-Farber Cancer Institute, Harvard - Boston
Hematology/Oncology
Fellow
Residency Children's Hospital, Harvard - Boston
Pediatrics
Resident
Internship Children's Hospital, Harvard - Boston
Pediatrics
Intern
Professional Medical University of California
Medicine
M.D.
Doctoral Training University of California - Christopher Denny Lab
Molecular Biology
Ph.D.
Undergraduate Brandeis University
Biochemistry
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick S(2013)Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.  Oncogene, 32(42),5089-100
  2. Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick S(2013)A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group.  Frontiers in Oncology, 357
  3. Wiles ET, Lui-Sargent B, Bell R, Lessnick S(2013)BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma.  PLoS ONE, 8(3),e59369
  4. Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor E(2013)Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.  Frontiers in Oncology, 3141
  5. Sankar S, Tanner JM, Bell R, Chaturvedi A, Randall RL, Beckerle MC, Lessnick S(2013)A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.  Molecular and Cellular Biology, 33(22),4448-60
  6. Sankar S, Gomez NC, Bell R, Patel M, Davis IJ, Lessnick SL, Luo (2013)EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma.  Genes & Cancer, 4(5-6),213-23
  7. Wiles ET, Bell R, Thomas D, Beckerle M, Lessnick S(2013)ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma.  Genes & Cancer, 4(11-12),486-500
  8. DuBois SG, Goldsby R, Segal M, Woo J, Copren K, Kane JP, Pullinger CR, Matthay KK, Witte J, Lessnick SL, Robison LL, Bhatia S, Strong L(2012)Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study.  Pediatric Blood & Cancer, 59(1),52-6
  9. Luo W, Milash B, Dalley B, Smith R, Zhou H, Dutrow N, Cairns BR, Lessnick S(2012)Antibody detection of translocations in Ewing sarcoma.  EMBO Molecular Medicine, 4(6),453-61
  10. Calvert GT, Randall RL, Jones KB, Cannon-Albright L, Lessnick S, Schiffman J(2012)At-risk populations for osteosarcoma: the syndromes and beyond.  Sarcoma, 2012152382
  11. Spraker HL, Price SL, Chaturvedi A, Schiffman JD, Jones KB, Lessnick SL, Beckerle M, Randall R(2012)The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm.  Frontiers in Oncology, 22
  12. Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schafer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein (2012)The first European interdisciplinary ewing sarcoma research summit.  Frontiers in Oncology, 254
  13. Beck R, Monument MJ, Watkins WS, Smith R, Boucher KM, Schiffman JD, Jorde LB, Randall RL, Lessnick S(2012)EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations.  Cancer Genetics, 205(6),304-12
  14. Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman J(2012)Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma.  Cancer Genetics, 205(7-8),391-404
  15. Evans CH, Liu F, Porter RM, O'Sullivan RP, Merghoub T, Lunsford EP, Robichaud K, Van Valen F, Lessnick SL, Gebhardt MC, Wells J(2012)EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.  Clinical Cancer Research, 18(19),5341-51
  16. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle M(2012)The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.  Genes & Cancer, 3(2),102-16
  17. Monument MJ, Lessnick SL, Schiffman JD, Randall R(2012)Microsatellite instability in sarcoma: fact or fiction?  ISRN Oncology, 2012473146
  18. Jones KB, Schiffman JD, Kohlmann W, Randall RL, Lessnick SL, Cannon-Albright L(2011)COMPLEX GENOTYPE SARCOMAS DISPLAY FAMILIAL INHERITANCE INDEPENDENT OF KNOWN CANCER PREDISPOSITION SYNDROMES.  Cancer Epidemiology, Biomarkers & Prevention,
  19. Lessnick SL, Kovar H, Houghton (2011)The molecular basis of sarcoma.  Sarcoma, 2011864130
  20. Sankar S, Lessnick S(2011)Promiscuous partnerships in Ewing's sarcoma.  Cancer Genetics, 204(7),351-65
  21. Joyner DE, Jones KB, Lessnick SL, Schiffman JD, Randall R(2011)Potential for modulation of the fas apoptotic pathway by epidermal growth factor in sarcomas.  Sarcoma, 2011847409
  22. Luo W, Kinsey M, Schiffman JD, Lessnick S(2011)Glutathione s-transferases in pediatric cancer.  Frontiers in Oncology, 139
  23. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P, Scotlandi (2010)CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.  Journal of Clinical Investigation, 120(3),668-80
  24. Randall RL, Lessnick SL, Jones KB, Gouw LG, Cummings JE, Cannon-Albright L, Schiffman J(2010)Is There a Predisposition Gene for Ewing's Sarcoma?  Journal of Oncology, 2010397632
  25. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor E(2010)Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.  Journal of Clinical Oncology, 28(12),1989-94
  26. Gangwal K, Close D, Enriquez CA, Hill CP, Lessnick S(2010)Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma.  Genes & Cancer, 1(2),177-187
  27. DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, Stegmaier (2009)Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.  Pediatric Blood & Cancer, 52(3),324-7
  28. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick S(2009)GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.  Oncogene,
  29. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick S(2009)EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.  Cancer Research, 69(23),9047-55

Review

  1. Gorlick R, Janeway K, Lessnick S, Randall RL, Marina (2013)Children's Oncology Group's 2013 blueprint for research: bone tumors.  Pediatric Blood & Cancer, 60(6),1009-15
  2. Lessnick SL, Ladanyi (2012)Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.  Annual Review of Pathology: Mechanisms of Disease, 7145-59
  3. Kowalewski AA, Randall RL, Lessnick S(2011)Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.  Sarcoma, 2011598704
  4. Toomey EC, Schiffman JD, Lessnick S(2010)Recent advances in the molecular pathogenesis of Ewing's sarcoma.  Oncogene, 29(32),4504-16
  5. Braun BS, Lessnick S(2009)Pediatric malignancies: update on sarcomas and leukemia development in children.  Current Opinion in Genetics & Development, 19(1),92-6
  6. Lessnick SL, Dei Tos AP, Sorensen PH, Dileo P, Baker LH, Ferrari S, Hall K(2009)Small round cell sarcomas.  Seminars in Oncology, 36(4),338-46

Clinical Trials

Video & News

Video